Myriad Genetics, Inc. (MYGN) Stock Overview
Explore Myriad Genetics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Myriad Genetics, Inc. (MYGN)
Key Financials
Key Financials
Market Cap
575.8M
P/E Ratio
-4.96
EPS (TTM)
$-0.13
ROE
-0.33%
MYGN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Myriad Genetics, Inc. (NASDAQ: MYGN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Myriad Genetics, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of MYGN on the NASDAQ shows an RSI of 76.76, suggesting the stock is in a an overbought condition. Our forecasting models predict a 12-month price target of $0.00 for the NASDAQ listing.
Key metrics behind Myriad Genetics, Inc.'s NASDAQ-traded stock include a P/E ratio of -4.96 and a market capitalization of 575.8M. Combined with our AI analysis, these give both institutional and retail investors a clear view of MYGN on the NASDAQ.